Fred Aslan, Chief Executive Officer and Director of Artiva Biotherapeutics, Inc., reported a sale of 61,888 shares of common stock on September 3, 2026. The sale was executed under a 'sell-to-cover' policy to satisfy tax withholding obligations related to the vesting of restricted stock units. The shares were sold at a...

This Form 4 filing reports a transaction by Subhashis Banerjee, Chief Medical Officer of Artiva Biotherapeutics, Inc. (NASDAQ: ARTV), a clinical-stage biopharmaceutical company. On September 3, 2026, Banerjee disposed of 1,100 shares of the company's Common Stock at a price of $11.1556 per share. Following the transact...

Jennifer Bush, COO, CLO, and Compliance Officer of Artiva Biotherapeutics, Inc., reported a disposition of 8,391 shares of common stock on September 3, 2026. The shares were sold at an average price of $11.1555 to cover tax withholding obligations related to the vesting of restricted stock units. These sales were execu...

Christopher Horan, Chief Tech Operations Officer at Artiva Biotherapeutics, Inc., reported a sale of 10,366 shares of common stock on September 3, 2026. The sale was executed under a "sell-to-cover" policy to satisfy tax withholding obligations related to the vesting of restricted stock units. The weighted average sale...

Fred Aslan, Chief Executive Officer and Director of Artiva Biotherapeutics, Inc., reported a sale of 61,888 shares of common stock on September 3, 2026. The sale was executed under a 'sell-to-cover' policy to satisfy tax withholding obligations related to the vesting of restricted stock units. The shares were sold at a...

Atara Biotherapeutics, Inc. (NASDAQ: ATRA) filed a Form 4 reporting a purchase of common stock by director Brian N. Cherry. On September 4, 2026, Mr. Cherry acquired 104,166 shares of common stock at a price of $9.60 per share, for an aggregate investment of approximately $1,000,000. Following this transaction, he bene...

On September 4, 2026, Wang Shoudong, Co-Chief Financial Officer of Atour Lifestyle Holdings Ltd (NASDAQ: ATAT), filed a Form 4 reporting the grant of employee stock options to purchase Class A Ordinary Shares. The reporting owner was awarded four separate tranches of 50,000 options each, totaling 200,000 options. Each ...

This filing details a transaction by Salvatore Privitera, Chief Technical Officer of AtriCure, Inc. (ATRC). On September 2, 2026, Mr. Privitera sold 7,763 shares of the company's Common Stock at a price of $52.50 per share. This sale was executed as part of a pre-arranged 10b5-1 trading plan adopted on February 20, 202...

Bruno Sousa Mauad, a director at Aura Minerals Inc., reported transactions involving Brazilian Depositary Receipts (BDRs) on September 3, 2026. Mauad acquired 1,000 BDRs at an average price of $29.1982, increasing their holdings to 13,559,160 BDRs. Concurrently, 250,000 BDRs were sold at a weighted average price of $29...

On September 2, 2026, Joseph A. Tyndall, a director of Axogen, Inc. (NASDAQ: AXGN), sold 3,500 shares of the company's common stock in a transaction reported on Form 4 filed September 4, 2026. The shares were sold at a weighted average price of $49.697 per share, with individual sales ranging from $48.01 to $51.46 per ...

This filing details a grant of 61,482 restricted stock units (RSUs) to Gregory Garrabrants, President and CEO of Axos Financial, Inc., on September 3, 2026. These RSUs were awarded under the company's 2014 stock incentive plan in connection with his employment contract. Each RSU represents a contingent right to one sha...

On March 10, 2026, Johnbull Okpara, Chief Accounting Officer of BANK OF AMERICA CORP /DE/, reported the disposition of 50 depositary shares of Preferred Stock, Series DD. Each depositary share represents a 1/25th interest in a share, with a redemption price of $1,000.00 per share. These shares were redeemed by the issu...

This is a Form 4 Statement of Changes in Beneficial Ownership filed on September 4, 2026, by Barings Corporate Investors (NYSE: MCI). The filing reports that Christina Emery, the company's President, acquired 39.7167 notional shares on September 3, 2026, through the Barings Non-Qualified Thrift Plan at a price of $18.9...

This filing details a transaction by Reich Sapire Rose Nicole Dominique, a director at BBB FOODS INC, involving 7,623 shares of Class A Common Stock on September 2, 2026. The shares were disposed of at a price of $50.50 per share, leaving a post-transaction holding of 7,623 shares. The transaction is noted as exempt fr...

Vincent Vellucci, a director at BEL FUSE INC /NJ, reported the sale of 393 shares of Class B Common Stock on September 2, 2026. The shares were sold at a weighted average price of $243.61, with individual transactions ranging from $243.61 to $243.65. Following these transactions, Vellucci owns 8434 shares of Class B Co...

On September 3rd, 2026, Ajit Jain, Vice Chairman of Berkshire Hathaway Inc., made a charitable gift of 10 shares of Class B Common Stock. Following this transaction, Mr. Jain directly owns 317 shares of Class B Common Stock. Additionally, various family trusts and the Jain Foundation Inc. hold a significant number of C...

This Form 4 filing reports a series of open-market sales of BILL Holdings, Inc. (BILL) common stock by Rene A. Lacerte, the company's CEO and a director. Between September 2 and September 3, 2026, Lacerte disposed of approximately 246,193 shares in ten separate transactions executed at weighted-average prices ranging f...

Patrick Villanova, Chief Financial Officer of BLACKLINE, INC., reported a transaction on September 2, 2026. He acquired 750 shares of Common Stock at a price of $14.00 per share. Following this transaction, he owns 131,812 shares of Common Stock. Additionally, Mr. Villanova exercised a stock option for 750 shares of Co...

This Form 4 filing reports a transaction by Subhashis Banerjee, Chief Medical Officer of Artiva Biotherapeutics, Inc. (NASDAQ: ARTV), a clinical-stage biopharmaceutical company. On September 3, 2026, Banerjee disposed of 1,100 shares of the company's Common Stock at a price of $11.1556 per share. Following the transact...

Wu Junhua, Chief Strategy Officer and Director at Baozun Inc., acquired 13,500 American Depositary Shares (ADS) on September 2, 2026. The transaction was made at a price of $2.85 per share. Following this acquisition, Wu Junhua directly owns 267,270 ADSs. This filing, Form 4, is significant as it details insider transa...

Neil Lindsay, CFO & Chief Business Officer of Alector, Inc., reported the sale of 29,251 common shares on September 3, 2026. The sale was executed at a weighted average price of $2.6648 per share, with individual transactions ranging from $2.49 to $2.75. This sale was conducted to satisfy tax obligations arising from t...

Stephen Feider, acting as Attorney-in-Fact for Saint Sean, reported the sale of 5,641 shares of Beta Bionics, Inc. Common Stock on September 3, 2026. The sale was conducted under a Rule 10b5-1 Plan adopted on September 5, 2025. The weighted average sale price was $20.0778, with prices ranging from $20.00 to $20.1696. F...

Block, Inc. director Anthony Mathew Eisen filed a Form 4 with the SEC on September 4, 2026, reporting the sale of 18,000 shares of Class A Common Stock. The sales were executed over three consecutive trading days—September 2, 3, and 4, 2026—with 6,000 shares sold each day at prices of $77.30, $83.57, and $82.51 per sha...

Lefferts Kelly, EVP, Chief Legal Officer of Bloomin' Brands, Inc., reported a transaction on September 2, 2026. Kelly acquired 15,385 shares of Common Stock through the vesting of Restricted Stock Units (RSUs) with a transaction price of $0.00. Following this acquisition, 3,747 shares were disposed of to cover taxes, r...

This Form 4 filing reports transactions by Philip J. Pace, Senior Vice President and Chief Accounting Officer of Bloomin' Brands, Inc. (NASDAQ: BLMN), for the period ending September 2, 2026. On that date, 15,385 restricted stock units (RSUs) granted on September 2, 2025, fully vested. Each RSU represented the continge...